CASI Pharmaceuticals has acquired a portfolio of 25 U.S. FDA-approved abbreviated new drug applications (ANDAs), one ANDA that FDA tentatively approved, and three ANDAs that are pending FDA approval. The portfolio was acquired from Sandoz.   CASI intends to select and commercialize certain products from the portfolio that have unique market opportunity and cost-effective manufacturing in China and/or in the U.S.    Ken Ren, Ph.D., CASI’s chief executive officer, said, &#822...